Investment Analysts’ Recent Ratings Updates for GoodRx (GDRX)

Several brokerages have updated their recommendations and price targets on shares of GoodRx (NASDAQ: GDRX) in the last few weeks:

• 5/23/2024 – GoodRx was upgraded by analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating. They now have a $10.00 price target on the stock, up previously from $8.00.
• 5/20/2024 – GoodRx had its price target raised by analysts at Barclays PLC from $9.00 to $10.00. They now have an “overweight” rating on the stock.
• 5/16/2024 – GoodRx was upgraded by analysts at Raymond James from a “market perform” rating to an “outperform” rating. They now have a $10.00 price target on the stock.
• 5/16/2024 – GoodRx had its price target raised by analysts at TD Cowen from $14.00 to $16.00. They now have a “buy” rating on the stock.
• 4/10/2024 – GoodRx was upgraded by analysts at KeyCorp from a “sector weight” rating to an “overweight” rating. They now have a $9.00 price target on the stock.
• 3/25/2024 – GoodRx was upgraded by analysts at Wells Fargo & Company from an “equal weight” rating to an “overweight” rating. They now have a $10.00 price target on the stock, up previously from $7.50.

GoodRx Trading Up 0.6 %

GDRX traded up $0.04 during trading on Thursday, hitting $7.24. 1,461,256 shares of the stock were exchanged, compared to its average volume of 1,552,484. The firm has a 50 day simple moving average of $6.96 and a 200 day simple moving average of $6.51. The firm has a market cap of $2.72 billion, a price-to-earnings ratio of -723.28, a P/E/G ratio of 2.47 and a beta of 1.37. GoodRx Holdings, Inc. has a 1 year low of $4.14 and a 1 year high of $9.37. The company has a debt-to-equity ratio of 1.02, a quick ratio of 6.29 and a current ratio of 6.29.

GoodRx (NASDAQ:GDRX) last announced its quarterly earnings results on Thursday, February 29th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.02. GoodRx had a positive return on equity of 3.45% and a negative net margin of 0.86%. The business had revenue of $196.64 million for the quarter, compared to the consensus estimate of $195.59 million. As a group, equities analysts expect that GoodRx Holdings, Inc. will post 0.23 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in GDRX. Beacon Capital Management LLC acquired a new stake in GoodRx during the 1st quarter worth about $28,000. Citigroup Inc. lifted its position in GoodRx by 301.7% during the 3rd quarter. Citigroup Inc. now owns 7,997 shares of the company’s stock worth $45,000 after acquiring an additional 6,006 shares during the period. Gerber LLC acquired a new stake in GoodRx during the 4th quarter worth about $75,000. Schnieders Capital Management LLC acquired a new stake in GoodRx during the 1st quarter worth about $93,000. Finally, Innealta Capital LLC acquired a new stake in GoodRx during the 4th quarter worth about $91,000. 63.77% of the stock is currently owned by hedge funds and other institutional investors.

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.